Drugs / RNF
last change Jul 2011 re-read 3 minutes ago

RNF

Developed for
multiple sclerosis

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT00404352 Comparator Nov 2006 → Aug 2010 multiple sclerosis Merck KGaA, Darmstadt, Germany Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RNF ClinicalTrials.gov intervention name — accepted as the source's own label NCT00404352 ↗
Route Subcutaneous “RNF administered subcutaneously three times weekly” NCT00404352 ↗